- On February 27, the FDA issued an Emergency Use Authorization for John
Personalized Medicine For Better Health
-
28, Feb 2021
-
5, Jan 2021
Latest Updates: (01/18/2021)
-
31, Dec 2020
Recurring symptoms lasting several months may require ongoing treatment in so
-
29, Dec 2020
A new variant of the coronavirus that causes COVID-19 has be
-
13, Dec 2020
Results of Phase 2/3 Clinical Trial:
About
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to
- - Assess disease risk for several immunological disorders.
- - Predict the success of a drug for a specific patient.
- - Develop dosing recommendations for new immunological drugs.
Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.
Contact
- +1 (855) 753-9474
- info@plexision.com
- 4424 Penn Ave., #202, Pittsburgh, PA 15224 USA